REFERENCES
- Khayat D. Innovative cancer therapies: Putting costs into context. Cancer. 2011 Sep 14.
- Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26(10): 1626–1634.
- Annemans L. Health Economics for non-economists. An introduction to the concepts, methods and pitfalls of health economic evaluations Academiapress 2008. ISBN 9789038212746; XIV + 106 p.
- Cleemput I, Neyt M, Thiry N, De Laet C, Leys M. Threshold values for cost-effectiveness in health care KCE reports 100 C. 2008.
- Trowman R, Chung H, Longson C, Littlejohns P, Clark P. The National Institute for Health and Clinical Excellence and its role in assessing the value of new cancer treatments in England and Wales. Clin CanRes. 2011; 17(15): 4930–4935.
- Trusheim MR, Burgess B, Hu SX, Long T, Averbuch SD, Flynn AA, Lieftucht A, Mazumder A, Milloy J, Shaw PM, Swank D, Wang J, Berndt ER, Goodsaid F, Palmer MC. Quantifying factors for the success of stratified medicine. Nat Rev Drug Discov. 2011; 10(11): 817–833.
- Pharmaprojects R & D Pipeline News Feed. Johnson & Johnson offers up a money-back deal for Velcade. 13 Jun 2007. http://www.pharmaprojects.com/news/13061507.htm